Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Sodium-glucose transporter-2 inhibition as an antidiabetic therapy.

× No keyword cloud information.

8 in total

Review 1. Dapagliflozin in patients with type 2 diabetes mellitus.

Authors: Theodosios D Filippatos; Evangelos N Liberopoulos; Moses S Elisaf
Journal: Ther Adv Endocrinol Metab Date: 2015-02 Impact factor: 3.565

2. SGLT-2 Inhibitors: A New Mechanism for Glycemic Control.

Authors: Edward C Chao
Journal: Clin Diabetes Date: 2014-01

3. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

Authors: Julio Rosenstock; Naresh Aggarwal; David Polidori; Yue Zhao; Deborah Arbit; Keith Usiskin; George Capuano; William Canovatchel
Journal: Diabetes Care Date: 2012-04-09 Impact factor: 19.112

Review 4. Continual evolution of type 2 diabetes: an update on pathophysiology and emerging treatment options.

Authors: Susan Cornell
Journal: Ther Clin Risk Manag Date: 2015-04-16 Impact factor: 2.423

5. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.

Authors: Martin Ridderstråle; Robbyna Svaerd; Cordula Zeller; Gabriel Kim; Hans J Woerle; Uli C Broedl
Journal: Cardiovasc Diabetol Date: 2013-09-05 Impact factor: 9.951

Sodium-glucose transporter-2 inhibition as an antidiabetic therapy.

Review 1. Dapagliflozin in patients with type 2 diabetes mellitus.

2. SGLT-2 Inhibitors: A New Mechanism for Glycemic Control.

3. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

Review 4. Continual evolution of type 2 diabetes: an update on pathophysiology and emerging treatment options.

5. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.

Review 6. Energy Expenditure in People with Diabetes Mellitus: A Review.

7. Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?

8. Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition.